Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
不可切除的早期至中期肝细胞癌根治性转化治疗后阿特珠单抗联合贝伐珠单抗停药标准的提议:一项多中心概念验证研究
期刊:Journal of Gastroenterology
影响因子:5.5
doi:10.1007/s00535-025-02233-z
Aoki, Tomoko; Kudo, Masatoshi; Nishida, Naoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Tada, Toshifumi; Morita, Masahiro; Chishina, Hirokazu; Takita, Masahiro; Hagiwara, Satoru; Ida, Hiroshi; Minami, Yasunori; Kuroda, Hidekatsu; Nakamura, Noriaki; Hiraoka, Atsushi; Tomonari, Tetsu; Tani, Joji; Naganuma, Atsushi; Kakizaki, Satoru; Ogawa, Chikara; Hatanaka, Takeshi; Ishikawa, Toru; Kawata, Kazuhito; Takebe, Atsushi; Matsumoto, Ippei; Hidaka, Masaaki; Kurosaki, Masayuki; Kumada, Takashi; Izumi, Namiki